IL37 and psoriasis vulgaris: Pathogenesis is primarily driven by pro-inflammatory cytokines such as IL-12, IL-17, and IL-23, which have led to the development of biological therapies targeting these cytokines and related inflammatory pathways for the treatment of plaque psoriasis (6).